At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Study
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Irinotecan for Stomach Cancer and 2 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Cancer, Gastric Cancer, Chemotherapy Effect
CountriesEgypt
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedFeb 25, 2021
Enrollment StartMar 5, 2021
Primary CompletionJan 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.4 years ago
Interventions
Docetaxeldrug
patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
Irinotecandrug
patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival